Combining in vitro and in silico approaches to find new candidate drugs targeting the pathological proteins related to the Alzheimer's disease

Hui Li, Xiaobing Wang, Hongmei Yu, Jing Zhu, Hongtao Jin, Aiping Wang, Zhaogang Yang

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Background: Alzheimer’s disease (AD) as the most common cause of dementia among older people has aroused the universal concern of the whole world. However, until now there is still none effective treatments. Consequently, the development of new drugs targeting this complicated brain disorder is urgent and needs more efforts. In this review, we detailed the current state of knowledge about new candidate drugs targeting the pathological proteins especially the drugs which are employed using the combined methods of in vitro and in silico. Methods: We looked up and reviewed online papers related to the pathogenesis and new drugs development of AD. Then, articles up to the requirements were respectively analyzed and summa-ried to provide the latest knowledge about the pathogenic effect and the new candidate drugs targeting Aβ and Tau proteins. Results: New candidate drugs targeting the Aβ include decreasing the production, promoting the clearence and preventing aggregation. However these drugs have mostly failed in Phase III clinical trial stage due to the unsuccessful of reversing cognition symptoms. As to tau protein, the prevention of tau aggregation and propagation is a promising strategy to synthesize/design mechanism-based drugs against tauopathies. Some candidate drugs are under research. Moreover, because of the complex pathogenesis of AD, multi-target drugs have also shed light on the treatment of AD. Conclusion: Given to the consecutive failure of Aβ-directed drugs and the feasibilities of tau-targeted therapy, more and more researchers suggested that the AD treatment should be moved from Aβ to tau or focused on considering the soluble form of Aβ and tau as a whole. Moreover, the novel in silico methods also have great potential in drug discovery, drug repositioning, virtual screening of chemical libraries. No matter how many difficulties and challenges in prevention and treatment of AD, we firmly believe that the effective and safe drugs will be found using the combined methods in the immediate future with the global effort.

Original languageEnglish (US)
Pages (from-to)758-768
Number of pages11
JournalCurrent Neuropharmacology
Volume16
Issue number6
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Fingerprint

Drug Delivery Systems
Computer Simulation
Alzheimer Disease
Pharmaceutical Preparations
Proteins
tau Proteins
Drug Repositioning
Tauopathies
Small Molecule Libraries
Therapeutics
Phase III Clinical Trials
In Vitro Techniques
Brain Diseases
Drug Discovery
Cognition
Dementia
Research Personnel
Research

Keywords

  • AD new candidate drugs
  • Alzheimer’s disease
  • Amyloid β protein
  • In silico
  • In vitro
  • Tau protein

ASJC Scopus subject areas

  • Pharmacology
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Combining in vitro and in silico approaches to find new candidate drugs targeting the pathological proteins related to the Alzheimer's disease. / Li, Hui; Wang, Xiaobing; Yu, Hongmei; Zhu, Jing; Jin, Hongtao; Wang, Aiping; Yang, Zhaogang.

In: Current Neuropharmacology, Vol. 16, No. 6, 01.01.2018, p. 758-768.

Research output: Contribution to journalReview article

Li, Hui ; Wang, Xiaobing ; Yu, Hongmei ; Zhu, Jing ; Jin, Hongtao ; Wang, Aiping ; Yang, Zhaogang. / Combining in vitro and in silico approaches to find new candidate drugs targeting the pathological proteins related to the Alzheimer's disease. In: Current Neuropharmacology. 2018 ; Vol. 16, No. 6. pp. 758-768.
@article{20027a258a3149e992af58ebb6890125,
title = "Combining in vitro and in silico approaches to find new candidate drugs targeting the pathological proteins related to the Alzheimer's disease",
abstract = "Background: Alzheimer’s disease (AD) as the most common cause of dementia among older people has aroused the universal concern of the whole world. However, until now there is still none effective treatments. Consequently, the development of new drugs targeting this complicated brain disorder is urgent and needs more efforts. In this review, we detailed the current state of knowledge about new candidate drugs targeting the pathological proteins especially the drugs which are employed using the combined methods of in vitro and in silico. Methods: We looked up and reviewed online papers related to the pathogenesis and new drugs development of AD. Then, articles up to the requirements were respectively analyzed and summa-ried to provide the latest knowledge about the pathogenic effect and the new candidate drugs targeting Aβ and Tau proteins. Results: New candidate drugs targeting the Aβ include decreasing the production, promoting the clearence and preventing aggregation. However these drugs have mostly failed in Phase III clinical trial stage due to the unsuccessful of reversing cognition symptoms. As to tau protein, the prevention of tau aggregation and propagation is a promising strategy to synthesize/design mechanism-based drugs against tauopathies. Some candidate drugs are under research. Moreover, because of the complex pathogenesis of AD, multi-target drugs have also shed light on the treatment of AD. Conclusion: Given to the consecutive failure of Aβ-directed drugs and the feasibilities of tau-targeted therapy, more and more researchers suggested that the AD treatment should be moved from Aβ to tau or focused on considering the soluble form of Aβ and tau as a whole. Moreover, the novel in silico methods also have great potential in drug discovery, drug repositioning, virtual screening of chemical libraries. No matter how many difficulties and challenges in prevention and treatment of AD, we firmly believe that the effective and safe drugs will be found using the combined methods in the immediate future with the global effort.",
keywords = "AD new candidate drugs, Alzheimer’s disease, Amyloid β protein, In silico, In vitro, Tau protein",
author = "Hui Li and Xiaobing Wang and Hongmei Yu and Jing Zhu and Hongtao Jin and Aiping Wang and Zhaogang Yang",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/1570159X15666171030142108",
language = "English (US)",
volume = "16",
pages = "758--768",
journal = "Current Neuropharmacology",
issn = "1570-159X",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

TY - JOUR

T1 - Combining in vitro and in silico approaches to find new candidate drugs targeting the pathological proteins related to the Alzheimer's disease

AU - Li, Hui

AU - Wang, Xiaobing

AU - Yu, Hongmei

AU - Zhu, Jing

AU - Jin, Hongtao

AU - Wang, Aiping

AU - Yang, Zhaogang

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Alzheimer’s disease (AD) as the most common cause of dementia among older people has aroused the universal concern of the whole world. However, until now there is still none effective treatments. Consequently, the development of new drugs targeting this complicated brain disorder is urgent and needs more efforts. In this review, we detailed the current state of knowledge about new candidate drugs targeting the pathological proteins especially the drugs which are employed using the combined methods of in vitro and in silico. Methods: We looked up and reviewed online papers related to the pathogenesis and new drugs development of AD. Then, articles up to the requirements were respectively analyzed and summa-ried to provide the latest knowledge about the pathogenic effect and the new candidate drugs targeting Aβ and Tau proteins. Results: New candidate drugs targeting the Aβ include decreasing the production, promoting the clearence and preventing aggregation. However these drugs have mostly failed in Phase III clinical trial stage due to the unsuccessful of reversing cognition symptoms. As to tau protein, the prevention of tau aggregation and propagation is a promising strategy to synthesize/design mechanism-based drugs against tauopathies. Some candidate drugs are under research. Moreover, because of the complex pathogenesis of AD, multi-target drugs have also shed light on the treatment of AD. Conclusion: Given to the consecutive failure of Aβ-directed drugs and the feasibilities of tau-targeted therapy, more and more researchers suggested that the AD treatment should be moved from Aβ to tau or focused on considering the soluble form of Aβ and tau as a whole. Moreover, the novel in silico methods also have great potential in drug discovery, drug repositioning, virtual screening of chemical libraries. No matter how many difficulties and challenges in prevention and treatment of AD, we firmly believe that the effective and safe drugs will be found using the combined methods in the immediate future with the global effort.

AB - Background: Alzheimer’s disease (AD) as the most common cause of dementia among older people has aroused the universal concern of the whole world. However, until now there is still none effective treatments. Consequently, the development of new drugs targeting this complicated brain disorder is urgent and needs more efforts. In this review, we detailed the current state of knowledge about new candidate drugs targeting the pathological proteins especially the drugs which are employed using the combined methods of in vitro and in silico. Methods: We looked up and reviewed online papers related to the pathogenesis and new drugs development of AD. Then, articles up to the requirements were respectively analyzed and summa-ried to provide the latest knowledge about the pathogenic effect and the new candidate drugs targeting Aβ and Tau proteins. Results: New candidate drugs targeting the Aβ include decreasing the production, promoting the clearence and preventing aggregation. However these drugs have mostly failed in Phase III clinical trial stage due to the unsuccessful of reversing cognition symptoms. As to tau protein, the prevention of tau aggregation and propagation is a promising strategy to synthesize/design mechanism-based drugs against tauopathies. Some candidate drugs are under research. Moreover, because of the complex pathogenesis of AD, multi-target drugs have also shed light on the treatment of AD. Conclusion: Given to the consecutive failure of Aβ-directed drugs and the feasibilities of tau-targeted therapy, more and more researchers suggested that the AD treatment should be moved from Aβ to tau or focused on considering the soluble form of Aβ and tau as a whole. Moreover, the novel in silico methods also have great potential in drug discovery, drug repositioning, virtual screening of chemical libraries. No matter how many difficulties and challenges in prevention and treatment of AD, we firmly believe that the effective and safe drugs will be found using the combined methods in the immediate future with the global effort.

KW - AD new candidate drugs

KW - Alzheimer’s disease

KW - Amyloid β protein

KW - In silico

KW - In vitro

KW - Tau protein

UR - http://www.scopus.com/inward/record.url?scp=85048985957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048985957&partnerID=8YFLogxK

U2 - 10.2174/1570159X15666171030142108

DO - 10.2174/1570159X15666171030142108

M3 - Review article

C2 - 29086699

AN - SCOPUS:85048985957

VL - 16

SP - 758

EP - 768

JO - Current Neuropharmacology

JF - Current Neuropharmacology

SN - 1570-159X

IS - 6

ER -